# A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

> **NCT05351892** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 18 (actual)

## Conditions studied

- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Hot Flashes
- Healthy Volunteers

## Interventions

- **DRUG:** Elinzanetant (BAY3427080)

## Key facts

- **NCT ID:** NCT05351892
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-04
- **Primary completion:** 2022-06-09
- **Final completion:** 2022-06-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05351892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05351892, "A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05351892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*